Z12.89 Insurance Policy Changes

ICD-10 Z12.89 is officially defined as "Encounter for screening for malignant neoplasm of other sites." code Z12.89 is referenced in 4 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z12.89 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Nov 5, 2026Medium impact
High-Resolution Anoscopy (CPB 0808, reviewed 2026-10-29)
Aetna's Clinical Policy Bulletin 0808 (last reviewed 2026-10-29) restates when high-resolution anoscopy (HRA) is considered medically necessary: for diagnosing suspicious anal lesions in patients with abnormal anal findings and for guiding biopsy and ablation of high-grade anal intraepithelial neoplasia. HRA for screening asymptomatic persons, estimating treatment-failure risk after chemoradiotherapy, and routine surveillance after treated anal squamous cell carcinoma is listed as experimental/investigational/unproven. The source states no effective date for a new change; the listed effective date is 11/19/2010, and the next review is 09/09/2027.
Aetna · Identified Oct 30, 2026Medium impact
In Vivo Analysis of Gastro-Intestinal and Urothelial Lesions (CPB 0783, reviewed 2026-10-26)
Aetna Clinical Policy Bulletin 0783 addresses in vivo analysis of gastrointestinal and urothelial lesions. It considers confocal laser endomicroscopy, including Cellvizio probe-based confocal laser endomicroscopy, and in-vivo analysis of colorectal polyps experimental, investigational, or unproven for the indications listed, because the effectiveness of these approaches has not been established. The source lists CPT and ICD-10 codes as not covered for the indications in the policy and gives a last review date of 10/26/2026.
Aetna · Identified Aug 19, 2026Medium impact
In Vivo Analysis of Gastro-Intestinal and Urothelial Lesions (CPB 0783, reviewed 2025-12-11)
Aetna Clinical Policy Bulletin 0783 considers confocal laser endomicroscopy (including Cellvizio probe-based confocal laser endomicroscopy) experimental, investigational, or unproven for the indications it lists, because the effectiveness of these approaches has not been established. The listed indications include assessment of safe surgical margins during laryngectomy, confirmation of low-grade dysplasia and surveillance of Barrett's esophagus, diagnosis and histologic grading of bladder cancer, diagnosis and staging of lung cancer, diagnosis of prostate cancer, diagnosis of head and neck squamous cell carcinoma, differentiation of colorectal polyps during routine colonoscopy, and diagnosis of indeterminate biliary strictures and pancreatic lesions. The policy also lists elastic-scattering spectroscopy for colonic polyps, ERCP with optical endomicroscopy for biliary lesions, and in vivo analysis of colorectal polyps (including chromoendoscopy, endocytoscopy, narrow-band imaging, multi-band imaging and the Optical Biopsy System) as experimental, investigational, or unproven.
Aetna · Identified Aug 17, 2026Medium impact
High-Resolution Anoscopy (CPB 0808, reviewed 2025-11-20)
Aetna considers high-resolution anoscopy (HRA) medically necessary to diagnose a suspicious anal lesion in persons with abnormal anal physical findings, and for HRA guidance for biopsy and ablation of high-grade anal intraepithelial neoplasia. Aetna considers HRA experimental, investigational, or unproven for screening asymptomatic persons for anal dysplasia and anal cancer, for estimating the risk of treatment failure of anal canal carcinoma after chemoradiotherapy, and for surveillance after treatment for anal squamous cell carcinoma. Current evidence is insufficient to establish routine HRA surveillance after treated anal squamous cell carcinoma as universally medically necessary.

Watch Z12.89

Get one email when a payer policy names Z12.89, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z12.89?

There are 4 tracked policy changes affecting code Z12.89, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z12.89?

Payers that have issued tracked updates for code Z12.89 include: Aetna.

How do I get notified when code Z12.89 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z12.89. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z12.89?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

High-Resolution Anoscopy (CPB 0808, reviewed 2026-10-29)

In Vivo Analysis of Gastro-Intestinal and Urothelial Lesions (CPB 0783, reviewed 2026-10-26)

In Vivo Analysis of Gastro-Intestinal and Urothelial Lesions (CPB 0783, reviewed 2025-12-11)

High-Resolution Anoscopy (CPB 0808, reviewed 2025-11-20)

What insurance policy changes affect code Z12.89?

Which payers have updated policy for code Z12.89?

How do I get notified when code Z12.89 policy changes?

Why do payers change policies for code Z12.89?